BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kato H, Kanematsu M, Kondo H, Goshima S, Matsuo M, Hoshi H, Moriyama N. Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J Magn Reson Imaging. 2004;19:76-81. [PMID: 14696223 DOI: 10.1002/jmri.10425] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Bárcena C, Sra AK, Gao J. Applications of Magnetic Nanoparticles in Biomedicine. In: Liu JP, Fullerton E, Gutfleisch O, Sellmyer D, editors. Nanoscale Magnetic Materials and Applications. Boston: Springer US; 2009. pp. 591-626. [DOI: 10.1007/978-0-387-85600-1_20] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
2 Han JK, Kim SJ, Kim SH. Well-differentiated Hepatocellular Carcinoma. Korean J Hepatol 2007;13:427. [DOI: 10.3350/kjhep.2007.13.3.427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Yu JS, Chung JJ, Kim JH, Cho ES, Kim DJ, Ahn JH, Kim KW. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging. 2011;29:985-992. [PMID: 21616624 DOI: 10.1016/j.mri.2011.04.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
4 Chen R, Lii J, Chou C, Chang T, Chen W, Li C, Tu H. T2-weighted and T1-weighted Dynamic Superparamagnetic Iron Oxide (Ferucarbotran) Enhanced MRI of Hepatocellular Carcinoma and Hyperplastic Nodules. Journal of the Formosan Medical Association 2008;107:798-805. [DOI: 10.1016/s0929-6646(08)60193-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Kim SH, Choi D, Kim SH, Lim JH, Lee WJ, Kim MJ, Lim HK, Lee SJ. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2005;184:1069-1076. [PMID: 15788575 DOI: 10.2214/ajr.184.4.01841069] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
6 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
8 Li CS, Chen RC, Tu HY, Shih LS, Zhang TA, Lii JM, Chen WT, Duh SJ, Chiang LC. Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography. Br J Radiol. 2006;79:659-665. [PMID: 16641423 DOI: 10.1259/bjr/12699987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
9 Park HS, Lee JM, Kim SH, Chang S, Kim SJ, Han JK, Choi BI. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. J Magn Reson Imaging. 2009;29:328-335. [PMID: 19161184 DOI: 10.1002/jmri.21615] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
10 Kim SH, Lee WJ, Lim HK, Park CK. SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol 2009;10:112-20. [PMID: 19270856 DOI: 10.3348/kjr.2009.10.2.112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
11 Li YW, Chen ZG, Wang JC, Zhang ZM. Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World J Gastroenterol 2015;21:4334-44. [PMID: 25892885 DOI: 10.3748/wjg.v21.i14.4334] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
12 Tanaka Y, Nakazawa T, Inoue T, Yamane K, Kubota K, Uojima H, Takada J, Okuwaki Y, Hidaka H, Shibuya A, Kokubu S, Matsunaga K, Koizumi W. Superparamagnetic iron oxide-enhanced magnetic resonance imaging is useful in predicting malignant potential of vascular transformation of hypointense hypovascular nodules on gadoxetic acid-enhanced magnetic resonance imaging. Hepatol Res 2017;47:1118-26. [PMID: 27943555 DOI: 10.1111/hepr.12850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
14 Okada M, Imai Y, Kim T, Kogita S, Takamura M, Kumano S, Onishi H, Hori M, Fukuda K, Hayashi N. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2010;32:903-913. [PMID: 20882621 DOI: 10.1002/jmri.22333] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
15 Tonan T, Fujimoto K, Azuma S, Ono N, Matsushita S, Kojiro M, Hayabuchi N. Evaluation of small (<or=2 cm) dysplastic nodules and well-differentiated hepatocellular carcinomas with ferucarbotran-enhanced MRI in a 1.0-T MRI unit: utility of T2*-weighted gradient echo sequences with an intermediate-echo time. Eur J Radiol 2007;64:133-9. [PMID: 17408900 DOI: 10.1016/j.ejrad.2007.02.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
16 Li C, Chen R, Lii J, Chen W, Shih L, Zhang T, Tu H. Magnetic Resonance Imaging Appearance of Well-differentiated Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2006;30:597-603. [DOI: 10.1097/00004728-200607000-00008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
17 Buell JF, Tranchart H, Cannon R, Dagher I. Management of Benign Hepatic Tumors. Surgical Clinics of North America 2010;90:719-35. [DOI: 10.1016/j.suc.2010.04.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
18 Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
19 Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Review of Cardiovascular Therapy 2014;3:705-15. [DOI: 10.1586/14779072.3.4.705] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]